IL17A and experimental autoimmune encephalomyelitis: It was previously shown that daily intra-peritoneal doses of these drugs were able to reduce the clinical severity of a murine model of IL-17A-mediated experimental autoimmune encephalomyelitis (EAE) [35, 37].